William M. Sikov
- Oncology top 1%
- Cancer Research top 0.5%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Pathology and Forensic Medicine top 2%
- Co-authors
- Mehra GolshanGeorge SomloEric P. WinerDonald A. BerryClifford A. HudisLisa A. CareyConstance CirrincioneW. Fraser Symmans
- Topics
- Breast Cancer Treatment Studies (44 papers)Cancer Treatment and Pharmacology (33 papers)HER2/EGFR in Cancer Research (27 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
William M. Sikov
87 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 2.3k
- Cancer Research 1.7k
- Pulmonary and Respiratory Medicine 660
- Molecular Biology 590
- Pathology and Forensic Medicine 553
Countries citing papers authored by William M. Sikov
This map shows the geographic impact of William M. Sikov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William M. Sikov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William M. Sikov more than expected).
Fields of papers citing papers by William M. Sikov
This network shows the impact of papers produced by William M. Sikov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William M. Sikov. The network helps show where William M. Sikov may publish in the future.
Co-authorship network of co-authors of William M. Sikov
This figure shows the co-authorship network connecting the top 25 collaborators of William M. Sikov. A scholar is included among the top collaborators of William M. Sikov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William M. Sikov. William M. Sikov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 21 | |
| 3 | 26 | |
| 4 | 2 | |
| 5 | Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast Cancerbreakdown → | 235 |
| 6 | 43 | |
| 7 | 60 | |
| 8 | 75 | |
| 9 | 38 | |
| 10 | 14 | |
| 11 | 44 | |
| 12 | A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25). | 1 |
| 13 | 25 | |
| 14 | Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)breakdown → | 650 |
| 15 | 48 | |
| 16 | 8 | |
| 17 | 22 | |
| 18 | 35 | |
| 19 | 5 | |
| 20 | 67 |
About William M. Sikov
William M. Sikov is a scholar working on Cancer Research, Oncology and Internal Medicine, having authored 93 papers that have together received 3.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (44 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (27 papers). The work is most often cited by research in Cancer Research (1.7k citations), Oncology (2.3k citations) and Pathology and Forensic Medicine (553 citations). William M. Sikov has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Mehra Golshan, George Somlo, Eric P. Winer, Donald A. Berry, Clifford A. Hudis, Lisa A. Carey, Constance Cirrincione, W. Fraser Symmans, Elisa Port and Charles M. Perou. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.